GlassScriptPhysician profile
Trang T Brownlee
NPI 1235447780
$10,662.75
in general payments reported to CMS, 2019-2025
26 companies · $2,673 in 2025
The $2,673 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,240 · 2022: $2,273 · 2023: $1,819 · 2024: $2,656 · 2025: $2,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,890 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,889.90 |
| Education | $258.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,577.97 | 2021-2025 | |
| Janssen Biotech, INC. | $1,500.53 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $1,239.41 | 2022-2025 | Sotyktu |
| Amgen INC. | $865.82 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $849.13 | 2021-2025 | |
| Lilly USA, LLC | $669.96 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Genzyme Corporation | $535.99 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $420.30 | 2021-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $390.73 | 2022-2024 | Vtama |
| Leo Pharma INC. | $378.10 | 2021-2025 | Adbry, Anzupgo |
| Ucb, INC. | $222.59 | 2021-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $173.29 | 2021-2024 | Blu-U |
| Galderma Laboratories, L.P. | $148.17 | 2021-2025 | Nemluvio |
| Incyte Corporation | $127.60 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $89.37 | 2023-2025 | Zoryve |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $89.35 | 2021 | |
| Mayne Pharma Commercial LLC | $68.61 | 2021-2023 | |
| Almirall LLC | $64.88 | 2021-2022 | |
| Genentech USA, INC. | $59.07 | 2021-2022 | |
| Organon LLC | $58.13 | 2024-2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.30 | 2023-2024 | Spevigo |
| Dermira, INC. | $21.60 | 2021 | |
| Vyne Pharmaceuticals INC. | $21.40 | 2021 | |
| Verrica Pharmaceuticals INC. | $15.93 | 2024 | Ycanth |
| Smith+Nephew, INC. | $15.33 | 2021 | |
| Kerecis Limited | $9.19 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trang Brownlee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.